Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun 10;22(12):6266.
doi: 10.3390/ijms22126266.

Active Surveillance in Prostate Cancer: Role of Available Biomarkers in Daily Practice

Belén Pastor-Navarro  1   2 , José Rubio-Briones  3 , Ángel Borque-Fernando  4 , Luis M Esteban  5 , Jose Luis Dominguez-Escrig  3 , José Antonio López-Guerrero  1   2   6
Affiliations
Review

Active Surveillance in Prostate Cancer: Role of Available Biomarkers in Daily Practice

Belén Pastor-Navarro et al. Int J Mol Sci. .

Abstract

Prostate cancer (PCa) is the most commonly diagnosed cancer in men. The diagnosis is currently based on PSA levels, which are associated with overdiagnosis and overtreatment. Moreover, most PCas are localized tumours; hence, many patients with low-/very low-risk PCa could benefit from active surveillance (AS) programs instead of more aggressive, active treatments. Heterogeneity within inclusion criteria and follow-up strategies are the main controversial issues that AS presently faces. Many biomarkers are currently under investigation in this setting; however, none has yet demonstrated enough diagnostic ability as an independent predictor of pathological or clinical progression. This work aims to review the currently available literature on tissue, blood and urine biomarkers validated in clinical practice for the management of AS patients.

Keywords: active surveillance; clinical biomarkers; prostate cancer; risk predictors.

PubMed Disclaimer

Conflict of interest statement

Authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Workflow diagram of the references’ selection process. Bibliography was selected considering different sources of biomarkers including tissue, blood and urine.
See this image and copyright information in PMC

References

    1. Cancer Today. [(accessed on 12 January 2021)]; Available online: https://gco.iarc.fr/today/online-analysis-multi-bars?v=2020&mode=cancer&....
    1. American Cancer Society . American Cancer Society; 2017. [(accessed on 12 April 2021)]. Prostate Cancer Early Detection, Diagnosis; pp. 1–25. Available online: https://www.cancer.org/content/dam/CRC/PDF/Public/8795.00.pdf.
    1. Parker C., Gillessen S., Heidenreich A., Horwich A. Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2015;26:v69–v77. doi: 10.1093/annonc/mdv222. - DOI - PubMed
    1. Aslam N., Nadeem K., Noreen R. JAC Prostate Cancer Prostate Cancer. Abeloff’s Clin. Oncol. 5/e. 2015;8:938–944.
    1. Mottet N., Bellmunt J., Briers E., van den Bergh R., Bolla M., van Casteren N., Cornford P., Culine S., Joniau S., Lam T., et al. European Association of Urology; 2015. [(accessed on 12 April 2021)]. Pocket Guidelines on Prostate Cancer. Available online: https://uroweb.org/wp-content/uploads/09-Prostate-Cancer_LR.pdf.